Arcadia Biosciences (RKDA) Announces $5.0 Million Registered Direct Offering Priced At-The-Market

Rhea-AI Summary

Arcadia Biosciences (Nasdaq: RKDA) announced a registered direct offering of 4,722,506 shares of common stock at $1.05876 per share, totaling approximately $5 million in gross proceeds. The offering is part of a three-year initiative, Project Greenfield, aimed at expanding its GoodWheat brand and driving growth in core products. The offering, facilitated by H.C. Wainwright & Co., is set to close on or around August 16, 2022, pending usual conditions. The unregistered investment options for additional shares will also be made available, exercisable at $0.93376 per share.

Positive

• Project Greenfield aims to enhance profitability and expand retail presence for GoodWheat.
• The offering is expected to raise approximately $5 million before expenses, providing essential funding.

Negative

• Potential dilution of existing shares due to the issuance of new shares in the offering.

DAVIS, Calif., Aug. 12, 2022 /PRNewswire/ -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 4,722,506 shares of its common stock (or common stock equivalents) at a purchase price of $1.05876 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the company agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 4,722,506 shares of common stock. The unregistered investment options will be exercisable immediately upon issuance at an exercise price of $0.93376 per share and will expire five years from the date of issuance. 

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The aggregate gross proceeds to Arcadia of both offerings are expected to be approximately $5 million before deducting placement agent fees and other offering expenses. The company intends to use the net proceeds from the offerings to support Project Greenfield, its three-year plan to unlock the company's potential and create a path to profitability. Project Greenfield aligns company resources around several key goals, including expanding retail for the company's GoodWheat^TM high-fiber pasta, driving growth in its other core brands and partnerships and maintaining an agile organization to cultivate next-generation wellness products.   

The registered direct offering is expected to close on or about August 16, 2022, subject to the satisfaction of customary closing conditions.

The shares of common stock (or common stock equivalents), excluding the investment options and the shares of common stock underlying the investment options, are being offered by Arcadia pursuant to a "shelf" registration statement on Form S-3 (File No. 333-264425) previously filed with the U.S. Securities and Exchange Commission (SEC) on April 21, 2022, and declared effective by the SEC on May 12, 2022. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Alternatively, when available, electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by email at placements@hcwco.com or by phone at (646) 975-6996.

The unregistered investment options described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (Act) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the investment options, have not been registered under the Act or applicable state securities laws. Accordingly, the investment options and the shares of common stock underlying the investment options may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Arcadia has agreed to file a registration statement with the SEC covering the resale of the unregistered shares issuable upon exercise of the investment options.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating crops to provide high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products that make every body feel good, inside and out. The company's food, beverage and body care products include GoodWheat™, Zola^® coconut water, ProVault™ topical pain relief and SoulSpring™ bath and body care. For more information, visit www.arcadiabio.com.

Safe Harbor Statement
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about the company, including statements relating to the company's expectations regarding the completion of the offering, satisfaction of closing conditions and use of proceeds therefrom. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, without limitation, market and other conditions, the future capital requirements of the company are different than expected, the closing conditions related to the registered direct offering are not satisfied and other risks set forth in the company's filings with the Securities and Exchange Commission from time to time, including the section entitled "Risk Factors" and additional information that will be set forth in its Form 10-K for the year ended December 31, 2021, and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.

View original content to download multimedia:https://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-announces-5-0-million-registered-direct-offering-priced-at-the-market-301605290.html

SOURCE Arcadia Biosciences, Inc.

FAQ

What is the purpose of Arcadia Biosciences' recent $5 million offering?

The offering aims to fund Project Greenfield, focusing on profitability and growth of its product lines.

When is the expected closing date for the Arcadia Biosciences stock offering?

The expected closing date is on or about August 16, 2022.

What is the stock price for the shares being offered by Arcadia Biosciences?

The shares are being offered at a price of $1.05876 per share.

What will be the exercise price for the unregistered investment options?

The investment options will have an exercise price of $0.93376 per share.

Who is acting as the placement agent for Arcadia Biosciences' offering?

H.C. Wainwright & Co. is the exclusive placement agent for the offering.